7 Results for "

DME

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "DME" in MCE Product Catalog:

Cat. No.: HY-P99116
CAS No.: 1607793-29-2
Synonyms: RG7716; RO-6867461
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .
loading...
    loading...
Cat. No.: HY-150069
CAS No.: 2271269-01-1
Purity:  99.16%
Target:  

Bcl-2 Family Apoptosis

Research Areas:  

Metabolic Disease

UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR) .
loading...
    loading...
Cat. No.: HY-P99830
CAS No.: 1227158-72-6
Synonyms: KH902
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC50 = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (Kd = 0.5 pM), VEGF-B (Kd = 8 pM), VEGF-C, and PlGF (Kd = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) .
loading...
    loading...
Cat. No.: HY-141028
CAS No.: 2062663-61-8
Target:  

PROTAC Linkers

Research Areas:  

Cancer

N,N'-DME-N,N'-Bis-PEG2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
loading...
    loading...
Cat. No.: HY-140163
CAS No.: 2279944-69-1
Target:  

PROTAC Linkers

Research Areas:  

Cancer

N,N'-DME-N-PEG2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs .
loading...
    loading...
Cat. No.: HY-N9535A
CAS No.: 89560-97-4
(R)-tert-OMe-byakangelicin is a kind of furanocoumarin, which has inhibitory activity to liver drug metabolizing enzyme (DME) activity. (R)-tert-OMe-byakangelicin can be isolated from immature fruits of Angelica sinensis .
loading...
    loading...
Cat. No.: HY-114606
CAS No.: 1673557-43-1
Research Areas:  

Cancer

SW208108 is a prodrug of dMe-SW208108, a CYP4F11-activated SCD inhibitor, with an IC50 value of 9 nM. SW208108 undergoes demethylation by CYP4F11 to form the active metabolite dMe-SW208108, thereby inhibiting enzyme function. SW208108 depletes unsaturated fatty acids, induces cytotoxicity in non-small cell lung cancer (NSCLC) cells expressing CYP4F11, and does not affect SCD activity in mouse sebocytes. SW208108 can be used in studies related to NSCLC .
loading...
    loading...